RZLT · Rezolute, Inc.

The thesis

Rezolute's value rests on the full upLIFT study of ersodetug in tumor hyperinsulinism (low blood sugar caused by excess insulin from tumors), and the company has dated the result: topline is due in mid-December 2026. The final responder rate against the 7-of-8 interim settles the case.

The shares closed at $4.22 on 28 October 2026, 61.4% below the 52-week high of $10.94 and down 10.6% over three months (split- and dividend-adjusted daily closes). The 14-period relative strength index (RSI) was 40.6. The close was $3.90 on 15 October 2026 and $3.84 on 18 September 2026, when the shares were deeply oversold.

The narrative is maturing: the topline date is set and a search of company news found no new disclosure after the 14 October 2026 enrollment release. The sunRIZE trial in congenital hyperinsulinism missed its primary endpoint (company topline, 11 December 2025), so the tumor study carries the pipeline.

Bullish and bearish views on Rezolute, Inc.

The bull case on Rezolute, Inc. (RZLT), in brief: The topline has a date. The bear case: Eight more participants can dilute the rate.

Bull case

• The topline has a date. Rezolute said on 14 October 2026 that enrollment is complete and topline is due in mid-December 2026. The 24 September 2026 release had only said "before end of 2026."
• The interim was strong. Seven of the first eight upLIFT participants met the primary endpoint, up from six on 2 June 2026 (company release, 24 September 2026). The study is single-arm and open-label, with up to 16 participants.
• The FDA left the congenital door open. On 5 October 2026 Rezolute reported that the FDA recommended a Type B pre-BLA (biologics license application) meeting for ersodetug in congenital hyperinsulinism after reviewing sunRIZE. The agency did not opine on approvability.
• Analyst targets sit far above the price. On 6 October 2026 Cantor Fitzgerald upgraded the shares to Overweight, Citizens raised its target to $15 and Lake Street raised its target to $12 (Benzinga). Maxim's target is $14 (3 June 2026), Guggenheim's is $11 (15 June 2026) and HC Wainwright's is $10 (25 September 2026).
• Cash was $107.8 million at 30 June 2026. The fiscal fourth-quarter net loss was $20.5 million (company release, 24 September 2026).

Bear case

• Eight more participants can dilute the rate. The interim covers half of the study. A final responder share well below 7 of 8 would remove the second indication after the sunRIZE miss. Eight participants is too small a sample to support a conclusion about the final rate.
• The shares have not rewarded the news. The close was $4.22 on 28 October 2026, against $4.01 on 2 October 2026, before the FDA recommendation, the upgrade and the target increases. The 3-month change is still negative at 10.6%.
• Spending is rising. General and administrative expense was $29.2 million in fiscal 2026 against $18.4 million in fiscal 2025. Cash fell from $120.3 million at 31 March 2026 to $107.8 million at 30 June 2026 (company releases).
• Financing could precede the readout. Prior financings used common stock plus pre-funded warrants. A raise before topline would dilute holders, and none appears in the 24 September 2026 or 14 October 2026 releases.
• The congenital path is unproven. The pre-BLA meeting is undated, and the FDA said any approvability view would come only in a formal BLA review (company release, 5 October 2026).

Price setup

The shares closed at $4.22 on 28 October 2026. That is above the 18 September 2026 close of $3.84 and the 15 October 2026 close of $3.90, and well below the 52-week high of $10.94. The RSI of 40.6 is neutral-to-weak, up from 24.0 on 18 September 2026.

Crowding evidence is limited. Five brokerages publish targets of $10 to $15, all well above the price. A quarterly report is estimated for about 6 November 2026. No insider sales or share issuance since 14 October 2026 turned up in company news or filings. A mid-December binary is the main source of price risk, and gaps can be wide in both directions in a microcap with no revenue.

A daily close below $3.70 would take the shares under the September oversold low and would break the case as written, whatever the company says.

Catalysts, next 30 days

• ~6 November 2026, est.: fiscal first-quarter 2027 results. The date is estimated from prior-year timing (6 November 2025 and 7 November 2024). The report shows cash after the $20.5 million fiscal fourth-quarter loss and whether the mid-December timing holds.
• Undated, 2026: Type B pre-BLA meeting. The FDA's view on a filing path after the sunRIZE miss would add or remove a second program.
• Mid-December 2026: upLIFT full topline. The date falls outside the 30-day window, but the case turns on it.

What would change the view

The case breaks if the final upLIFT responder rate lands well below the 7-of-8 interim, if topline slips from mid-December into 2027, or if Rezolute prices an equity offering before the readout. Cash falling faster than the $20.5 million fiscal fourth-quarter loss at the November report would also weaken the funded-binary framing. FDA feedback that the sunRIZE data cannot support a filing would remove the congenital option.

On price, a daily close below $3.70, under the 18 September 2026 close of $3.84, would end the case regardless of news.

What it trades with

Rezolute trades on its own clinical events more than on sector flows. The only recent sector-wide mention in company news was a 3 June 2026 gainers list that included RZLT alongside unrelated names. Small-cap biotech risk appetite and financing conditions affect the shares, but no comparison data shows how closely.